Capital Research Global Investors Reduces Stake in ASP Isotopes Inc.

Institutional investor sells over 800,000 shares of the advanced materials company.

Mar. 13, 2026 at 8:20am

Got story updates? Submit your updates here. ›

Capital Research Global Investors, a major institutional investor, has reduced its position in ASP Isotopes Inc. (NASDAQ:ASPI) by selling 824,495 shares in the third quarter. The firm now owns 2,043,567 shares, or a 2.19% stake, in the advanced materials company focused on isotope production and commercialization.

Why it matters

This sale by a prominent institutional investor could signal a shift in sentiment around ASP Isotopes, which has seen its stock price fluctuate over the past year. The company's success in commercializing its isotope technologies will be closely watched by the investment community.

The details

According to a regulatory filing, Capital Research Global Investors sold 824,495 shares of ASP Isotopes, reducing its stake in the company from 28.7% to 2.19%. The firm cited portfolio rebalancing as the reason for the sale. ASP Isotopes is developing technologies to produce various isotopes, including Molybdenum-100, Carbon-14, and Ytterbium-176, for medical and industrial applications.

  • Capital Research Global Investors sold the shares in the third quarter of 2026.

The players

Capital Research Global Investors

A major institutional investment firm that has reduced its stake in ASP Isotopes Inc.

ASP Isotopes Inc.

A development-stage advanced materials company focused on the production and commercialization of isotopes for medical and industrial applications.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

This sale by a major institutional investor highlights the ongoing scrutiny and volatility surrounding ASP Isotopes as it works to commercialize its isotope technologies. The company's ability to navigate the regulatory landscape and drive adoption of its products will be crucial in determining its long-term success.